Etiopathogenesis, diagnosis, and approaches to the treatment of arterial hypertension: an assessment of the physicians’ basic knowledge. Final results of the PHYSTARH project

Introduction. Arterial hypertension (AH) is a syndrome accompanied by an increase in systolic blood pressure (BP)≥140 mmHg and/or diastolic BP≥90 mmHg. It is a progressive pathology that affects the adult employable population and leads to the development of deadly complications. Aim. To compare the level of physicians’ knowledge in AH’s definition, diagnosis and treatment in different centers of Russia. Materials and methods. In the framework of the multicenter study PHYSTARH (the full name of the project “Physicians ‘and undergraduates’ knowledge in arterial hypertension treatment”), which was launched in 2017, an anonymous survey was conducted among 425 doctors from 9 cities/regions of Russia (Belgorod Region, Moscow, Krasnodar Territory, the Republic of Adygea, Voronezh, Primorye Territory, Tatarstan, Lipetsk, Chelyabinsk). Results. The study revealed an insufficient level of doctors’ knowledge in diagnosis and treatment of AH. Less than half of the respondents correctly answered the following questions: determining hypertension by the level of “home” monitoring of BP (36% of physicians), determining the degree of hypertension for the proposed numerical values (37% of physicians), definition and prevalence of the “refractory” hypertension (33% of physicians), definition of the “masked” hypertension (45% of physicians), the need for drug correction of high normal BP (9% of physicians), selection of the main classes of antihypertensive drugs without clinical situations (26% of physicians). Conclusion. The physicians’ knowledge on AH is unsatisfactory, despite the prevalence of pathology and the availability of clinical guidelines, which, in our view, justifies the need for additional public education programs for doctors in different regions.

arterial hypertension, arterial hypertension treatment, level of physicians’ knowledge, education programs for doctors, anonymous survey

1. Maroszynska-Dmoch EM, Wozakowska-Kaplon B. Coronary artery disease in young adults: linical and angiographic characterization. A single center study. Polish Heart J 2015; p. 1–17. doi: 10.5603/kp.a2015.0178

2. Chazova IE, Zhernakova YuV, Oshchepkova YeV. Prevalence of cardiovascular risk factors in Russian population of patients with arterial hypertension. Kardiologiya. 2014; 54 (10): 4–12 (in Russian)

3. Sundstrom J, Neovius M, Tynelius P, et al. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. BMJ 2011; 342: d643. doi: 10.1136/bmj.d643

4. Reddy VS, Jacob GP, Ballala K, et al. A study on the prevalence of hypertension among young adults in a coastal district of Karnataka, South India. Int J Healthcare Biomed Res 2015; 3 (3): 32–9.

5. Zadionchenko VS, Shekhyan GG, Timofeyeva NYu. Features of combined antihypertensive therapy in the modern treatment of arterial hypertension. Rus. med. zhurn. 2011; 19 (26): 1630–9 (in Russian)

6. Kontsevaya AV, Bates K, Goryachkin EA, et al. Hospital Stage of Myocardial Infarction Treatment in 13 Regions of Russian Federation by Results of the International Research. Rational Pharmacoth Cardiol 2018; 14 (4): 474–87. doi: 10.20996/1819-6446-2018-14-4-474-487

7. Danilenko LM, Klochkova GN, Kizilova IV, Pokrovskii MV. Metabolic cardioprotection: new concepts in implementation of cardioprotective effects of meldonium. Res Results Pharmacol 2016; 2 (3): 95–100. doi: 10.18413/2500-235x-2016-2-3-95-100

8. Bontsevich R, Chernykh A, Leonova A, et al. Physicians’ and undergraduates’ knowledge of drugs contraindicated for AH treatment. Eur J Clin Pharmacol 2019; 75 (Suppl. 1): S28 (EACPT-1241). The Abstracts: 14th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 29 June – 2 July 2019, Stockholm, Sweden. doi: 10.1007/s00228-019-02685-2

9. Leonova A, Bontsevich R, Chernykh A, et al. Assessment of physicians’ and senior medical students’ knowledge of antihypertensive drugs contraindications in COPD patients treatment. Eur J Clin Pharmacol 2019; 75 (Suppl. 1): S28 (EACPT-1263). The Abstracts: 14th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 29 June – 2 July 2019, Stockholm, Sweden. doi: 10.1007/s00228-019-02685-2

10. Bontsevich RA, Vovk YR, Gavrilova AA, et al. Physicians’ and senior medical students’ knowledge of drugs contraindicated for arterial hypertension treatment according to the PHYSTARH study. Sys Rev Pharm 2020; 11 (6): 26–30. doi: 10.31838/srp.2020.6.06

11. Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members, 2013. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens; 31 (7): 1281–357. doi: 10.1097/01.hjh.0000431740.32696.cc. PMID: 23817082.

12. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6–31 [Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16 (1): 6–31 (in Russian)]. doi: 10.26442/2075082X.2019.1.190179

13. Britov AN, Bystrova MM. Refractory hypertension – modern approaches to diagnostics and treatment. Rational Pharmacotherapy in Cardiology. 2010; 2 (in Russian). doi: 10.20996/1819-6446-2010-6-2-206-211

14. Tsibulkin NA. Resistant hypertension: from syndrome to diagnosis. Prakticheskaya meditsina. 2013; 3 (in Russian).

15. Gorbunov VM, Smirnova MI. Contemporary problems of evaluation of hypertension treatment efficacy: masked hypertension and white coat hypertension. Rational Pharmacotherapy in Cardiology. 2009; 3 (in Russian). doi: 10.20996/1819-6446-2009-5-3-76-82

16. Kobalava ZhD, Kotovskaya YuV. Ambulatory methods of blood pressure measurement in clinical practice. Eurasian Cardiology Journal. 2015; 3 (in Russian)

17. Lyamina NP, Nalivaeva AV, Senchikhin VN, Lipchanskaya TP. Masked hypertension in young persons: prevalence, significance of cardiovascularrisk factors and prognosis by gender differences. Russian Journal of Cardiology. 2017; 4: 7–12 (in Russian). doi: 10.15829/1560-4071-2017-4-7-12

18. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021–104. doi: 10.1093/eurheartj/ehy339

19. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87. doi: 10.1080/08037050701461084

20. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157–72. doi: 10.1097/01.hjh.0000194120.42722.ac

21. Vanhees L, Geladas N, Hansen D, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 2012; 19: 1005–33. doi: 10.1177/1741826711430926

22. Pribylov SA, Shabanov EA, Aliullin RV, et al. Endothelioprotective and hemodynamic effects of sartansin conjunction with arterial hypertension, coronary heart disease and chronic obstructive pulmonary disease. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. 2011; 16: 125–30 (in Russian).